WEKO3
アイテム
{"_buckets": {"deposit": "79ea5c99-eb35-4f62-acb3-3afb776c3783"}, "_deposit": {"id": "17395", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "17395"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00017395", "sets": ["1563"]}, "item_9_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2014-02", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1-2", "bibliographicPageEnd": "9", "bibliographicPageStart": "1", "bibliographicVolumeNumber": "76", "bibliographic_titles": [{"bibliographic_title": "Nagoya Journal of Medical Science"}]}]}, "item_9_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Carboplatin is a platinum-based anticancer drug that has been long used to treat many types of solid cancer. Because the clearance of carboplatin strongly correlates with the glomerular filtration rate (GFR), its dosage is calculated with the Calvert formula on the basis of the patient’s GFR to achieve the target area under the plasma drug concentration-time curve (AUC) for each patient. However, many lines of evidence from previous clinical studies should be interpreted with caution because different methods were used to estimate drug clearance and derive the dosage of carboplatin. There is a particularly high risk of carboplatin overdosing when the dosage is determined on the basis of standardized serum creatinine values. When deciding the dose of carboplatin for adult Japanese patients, preferred methods to assess renal function instead of directly measuring GFR include (1) 24-h urinary collection-based creatinine clearance adjusted by adding 0.2 mg/dl to the serum creatinine concentration measured by standardized methods, and (2) equation-based GFR (eGFR) with a back calculation to units of ml/min per subject. Given the limitations of serum creatinine-based GFR estimations, the GFR or creatinine clearance should be directly measured in each patient whenever possible. To ensure patient safety and facilitate a medical-team approach, the single most appropriate method available at each institute or medical team should be consistently used to calculate the dose of carboplatin with the Calvert formula.", "subitem_description_type": "Abstract"}]}, "item_9_identifier_60": {"attribute_name": "URI", "attribute_value_mlt": [{"subitem_identifier_type": "URI", "subitem_identifier_uri": "http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/7612/7612.html"}, {"subitem_identifier_type": "HDL", "subitem_identifier_uri": "http://hdl.handle.net/2237/19478"}]}, "item_9_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.18999/nagjms.76.1-2.1", "subitem_identifier_reg_type": "JaLC"}]}, "item_9_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Nagoya University School of Medicine"}]}, "item_9_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_9_source_id_7": {"attribute_name": "ISSN(print)", "attribute_value_mlt": [{"subitem_source_identifier": "0027-7622", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "ANDO, YUICHI"}], "nameIdentifiers": [{"nameIdentifier": "51082", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "SHIMOKATA, TOMOYA"}], "nameIdentifiers": [{"nameIdentifier": "51083", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "YASUDA, YOSHINARI"}], "nameIdentifiers": [{"nameIdentifier": "51084", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "HASEGAWA, YOSHINORI"}], "nameIdentifiers": [{"nameIdentifier": "51085", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2018-02-21"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "01_Ando.pdf", "filesize": [{"value": "198.5 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 198500.0, "url": {"label": "01_Ando.pdf", "url": "https://nagoya.repo.nii.ac.jp/record/17395/files/01_Ando.pdf"}, "version_id": "67c7b2bf-9fb5-4847-bdc3-1d46dd274784"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "carboplatin", "subitem_subject_scheme": "Other"}, {"subitem_subject": "pharmacokinetics", "subitem_subject_scheme": "Other"}, {"subitem_subject": "creatinine clearance", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Carboplatin Dosing for Adult Japanese Patients", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Carboplatin Dosing for Adult Japanese Patients"}]}, "item_type_id": "9", "owner": "1", "path": ["1563"], "permalink_uri": "https://doi.org/10.18999/nagjms.76.1-2.1", "pubdate": {"attribute_name": "公開日", "attribute_value": "2014-03-03"}, "publish_date": "2014-03-03", "publish_status": "0", "recid": "17395", "relation": {}, "relation_version_is_last": true, "title": ["Carboplatin Dosing for Adult Japanese Patients"], "weko_shared_id": null}
Carboplatin Dosing for Adult Japanese Patients
https://doi.org/10.18999/nagjms.76.1-2.1
https://doi.org/10.18999/nagjms.76.1-2.1bfc30ac2-3bf7-4b72-9f24-24625227dfea
名前 / ファイル | ライセンス | アクション |
---|---|---|
![]() |
|
Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2014-03-03 | |||||
タイトル | ||||||
タイトル | Carboplatin Dosing for Adult Japanese Patients | |||||
著者 |
ANDO, YUICHI
× ANDO, YUICHI× SHIMOKATA, TOMOYA× YASUDA, YOSHINARI× HASEGAWA, YOSHINORI |
|||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | carboplatin | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | pharmacokinetics | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | creatinine clearance | |||||
抄録 | ||||||
内容記述 | Carboplatin is a platinum-based anticancer drug that has been long used to treat many types of solid cancer. Because the clearance of carboplatin strongly correlates with the glomerular filtration rate (GFR), its dosage is calculated with the Calvert formula on the basis of the patient’s GFR to achieve the target area under the plasma drug concentration-time curve (AUC) for each patient. However, many lines of evidence from previous clinical studies should be interpreted with caution because different methods were used to estimate drug clearance and derive the dosage of carboplatin. There is a particularly high risk of carboplatin overdosing when the dosage is determined on the basis of standardized serum creatinine values. When deciding the dose of carboplatin for adult Japanese patients, preferred methods to assess renal function instead of directly measuring GFR include (1) 24-h urinary collection-based creatinine clearance adjusted by adding 0.2 mg/dl to the serum creatinine concentration measured by standardized methods, and (2) equation-based GFR (eGFR) with a back calculation to units of ml/min per subject. Given the limitations of serum creatinine-based GFR estimations, the GFR or creatinine clearance should be directly measured in each patient whenever possible. To ensure patient safety and facilitate a medical-team approach, the single most appropriate method available at each institute or medical team should be consistently used to calculate the dose of carboplatin with the Calvert formula. | |||||
内容記述タイプ | Abstract | |||||
出版者 | ||||||
出版者 | Nagoya University School of Medicine | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源 | http://purl.org/coar/resource_type/c_6501 | |||||
タイプ | departmental bulletin paper | |||||
ID登録 | ||||||
ID登録 | 10.18999/nagjms.76.1-2.1 | |||||
ID登録タイプ | JaLC | |||||
ISSN(print) | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0027-7622 | |||||
書誌情報 |
Nagoya Journal of Medical Science 巻 76, 号 1-2, p. 1-9, 発行日 2014-02 |
|||||
著者版フラグ | ||||||
値 | publisher | |||||
URI | ||||||
識別子 | http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/7612/7612.html | |||||
識別子タイプ | URI | |||||
URI | ||||||
識別子 | http://hdl.handle.net/2237/19478 | |||||
識別子タイプ | HDL |